Postpartum Preeclampsia Early Detection and Treatment: Nepal Pilot Study (PREDiCT-NPL)

Postpartum Preeclampsia Early Detection and Treatment: Using Biomarkers to Implement Risk-stratified Intervention (Nepal Pilot Randomized Controlled Trial)

The goal of this study is to address the significant morbidity associated with preeclampsia diagnosed after delivery. All participants will undergo biomarker evaluation with soluble fms-like tyrosine kinase-1 and placental growth factor (sFlt-1/PlGF) ratio testing before delivery to assess the predictive ability of these biomarkers with new-onset postpartum preeclampsia. High-risk participants will be randomized to a bundle of care strategies aimed at early detection and management of postpartum preeclampsia.

Study Overview

• Status: Recruiting
• Conditions: Postpartum Preeclampsia
• Intervention / Treatment: Other: Early detection and management of postpartum preeclampsia bundle

Detailed Description

This is a pilot randomized controlled trial of 60 normotensive, pregnant patients randomized to early monitoring and management for postpartum preeclampsia after biomarker evaluation with sFlt-1/PlGF ratio. After obtaining informed consent, participants will undergo preeclampsia risk assessment using sFlt-1/PlGF ratio testing prior to delivery. Patients with a low risk ratio will receive routine postpartum care. Patients with a high risk ratio will be randomized 1:1 to the intervention bundle focused on early detection and management of postpartum preeclampsia versus routine postpartum care. The intervention bundle will include remote blood pressure monitoring, education, and dispensing antihypertensive medication (nifedipine ER) for outpatient management of asymptomatic, mild-range BP. The primary outcome is the feasibility of all study procedures, measured by recruitment, retention, adherence, and acceptability. The secondary outcome is to assess the effect of early monitoring and management of postpartum preeclampsia on the composite outcome of hypertension requiring in-person medical evaluation and hypertension-related morbidity. Finally, the exploratory outcome is the predictive ability of sFlt-1/PlGF ratio of de novo postpartum preeclampsia in antenatally normotensive patients who are at risk for HDP based on ACOG/USPSTF criteria. Data on primary and secondary outcomes will be collected from both randomized groups and the non-randomized group with low-risk sFlt-1/PlGF ratio to determine the predictive capability of the test in the postpartum period.

• Study Type: Interventional
• Enrollment (Estimated): 60
• Phase: Not Applicable

Contacts and Locations

• Study Contact: Name: Alyssa Hernandez, DO; Phone Number: 4148055285; Email: alyhernandez@mcw.edu

Study Locations

• Nepal
  • Dhulikhel, Nepal
    • Recruiting
    • Dhulikhel Hospital
    • Contact: Abha Shrestha, MD; Phone Number: 0977-1-5522981; Email: abhaobgy@kusms.edu.np
    • Principal Investigator: Abha Shrestha, MD
• United States
  • Wisconsin
    • Milwaukee, Wisconsin, United States, 53226
      • Active, not recruiting
      • Medical College of Wisconsin

Participation Criteria

Eligibility Criteria

• Ages Eligible for Study: Adult; Older Adult
• Accepts Healthy Volunteers: No

Description

Inclusion Criteria:

• Pregnant patients ≥ 36 weeks gestation without major fetal anomalies
• Age ≥ 18 years
• Admitted for labor at Dhulikhel Hospital, or intend to deliver at Dhulikhel Hospital

• At risk for preeclampsia, using the Clinical Risk Assessment for Preeclampsia according to ACOG and USPSTF

  • 1 or more high risk factors:

    • History of preeclampsia
    • Type 1 or 2 diabetes
    • Multifetal gestation?
    • Renal disease
    • Autoimmune disease

  • 2 or more moderate risk factors:

    • Nulliparity
    • BMI > 30
    • First-degree relative with a history of preeclampsia
    • African American race
    • Low socioeconomic status
    • Age > 35 years
    • History of low birthweight or small for gestational age
    • Previous adverse pregnancy outcome
    • Interpregnancy interval > 10 years

Exclusion Criteria:

• Antenatal hypertensive disorder of pregnancy diagnosis, including gestational hypertension, preeclampsia, eclampsia, or HELLP syndrome, according to ACOG guidelines
• Chronic hypertension, according to ACOG guidelines
• Known allergy or contraindication to nifedipine
• Inability or unwillingness to provide informed consent
• Two or more blood pressures with an SBP ≥140 or DBP ≥90 after consent and prior to sFlt-1/PlGF testing (screen failure criteria)

Study Plan

How is the study designed?

Design Details

• Primary Purpose: Prevention
• Allocation: Randomized
• Interventional Model: Parallel Assignment
• Masking: Double

Number of Arms

3

Arms and Interventions

Participant Group / Arm	Intervention / Treatment
Experimental: High-risk Intervention; Participants with high-risk sFlt-1/PlGF ratio randomized to early detection and management of postpartum preeclampsia with remote blood pressure monitoring, education, and dispensing antihypertensive medication (nifedipine ER) for outpatient management of asymptomatic, mild range BP.	Other: Early detection and management of postpartum preeclampsia bundle; Remote blood pressure monitoring, education, and dispensing antihypertensive medication (nifedipine ER) for outpatient management of asymptomatic, mild range BP.
No Intervention: High-Risk Control; Participants with high-risk sFlt-1/PlGF ratio randomized to standard postpartum care.
No Intervention: Low-risk Control; Participants with low-risk sFlt-1/PlGF ratio will not be randomized, but will remain enrolled to assess the exploratory outcome of biomarker predictive ability.

What is the study measuring?

Primary Outcome Measures

Outcome Measure	Measure Description	Time Frame
Study feasibility	Assess study feasibility as measured by retention rate.	1 year

Secondary Outcome Measures

Outcome Measure	Measure Description	Time Frame
Composite outcome of hypertension-related healthcare utilization and morbidity.	Assess the effect of early monitoring and management of postpartum preeclampsia on the incidence of a composite outcome including hypertension requiring in-person medical evaluation and hypertension-related morbidity.	4 weeks postpartum
Predictive ability of sFlt-1/PlGF ratio for de novo postpartum preeclampsia	Assess the sFlt-1/PlGF ratio predictive ability of de novo postpartum preeclampsia in antenatally normotensive patients.	2 weeks postpartum

Collaborators and Investigators

• Sponsor: Medical College of Wisconsin
• Collaborators: Dhulikhel Hospital
• Investigators: Principal Investigator: Anna Palatnik, MD, Medical College of Wisconsin

Study record dates

Study Major Dates

• Study Start (Actual): March 3, 2026
• Primary Completion (Estimated): June 1, 2027
• Study Completion (Estimated): June 1, 2027

Study Registration Dates

• First Submitted: June 30, 2025
• First Submitted That Met QC Criteria: September 17, 2025
• First Posted (Actual): September 22, 2025

Study Record Updates

• Last Update Posted (Actual): July 20, 2026
• Last Update Submitted That Met QC Criteria: July 16, 2026
• Last Verified: July 1, 2026

More Information

Terms related to this study

• Keywords: Hypertension; Pregnancy; Postpartum; Preeclampsia
• Additional Relevant MeSH Terms: Urogenital Diseases; Vascular Diseases; Cardiovascular Diseases; Female Urogenital Diseases and Pregnancy Complications; Pregnancy Complications; Hypertension, Pregnancy-Induced; Pre-Eclampsia; Hypertension
• Other Study ID Numbers: PRO00056073

Plan for Individual participant data (IPD)

• Plan to Share Individual Participant Data (IPD)?: NO
• IPD Plan Description: Individual participant data will not be shared since this is a pilot study with very small sample sizes in each randomization group.

Drug and device information, study documents

• Studies a U.S. FDA-regulated drug product: No
• Studies a U.S. FDA-regulated device product: No